Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics

Zynerba Pharmaceuticals, Inc. (ZYNE): $1.32

0.02 (-1.49%)

POWR Rating

Component Grades








ZYNE Price/Volume Stats

Current price $1.32 52-week high $1.40
Prev. close $1.34 52-week low $0.25
Day low $1.32 Volume 1,099,200
Day high $1.33 Avg. volume 471,750
50-day MA $0.94 Dividend yield N/A
200-day MA $0.57 Market Cap 71.20M

ZYNE Stock Price Chart Interactive Chart >

Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio

Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.

ZYNE Latest News Stream

Event/Time News Detail
Loading, please wait...

ZYNE Latest Social Stream

Loading social stream, please wait...

View Full ZYNE Social Stream

Latest ZYNE News From Around the Web

Below are the latest news stories about ZYNERBA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.

Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc

On September 13, 2023, President Terri Sebree of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) sold 12,401 shares of the company's stock.

Yahoo | September 15, 2023

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q)DEVON, Pa., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsy

Yahoo | September 14, 2023

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | August 15, 2023

Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?

With Harmony Biosciences acquiring Zynerba Pharmaceuticals, ZYNE stock jumped on both the buyout and the underlying therapeutic implications.

Josh Enomoto on InvestorPlace | August 14, 2023

Harmony Biosciences to acquire Main Line's Zynerba in up to $200M deal

The centerpiece of Harmony Biosciences' deal is Zynerba's lead new drug candidate Zygel, a pharmaceutically produced transdermal cannabinoid therapy.

Yahoo | August 14, 2023

Read More 'ZYNE' Stories Here

ZYNE Price Returns

1-mo -0.38%
3-mo 300.49%
6-mo 213.24%
1-year 60.98%
3-year -59.76%
5-year -83.16%
YTD 149.06%
2022 -81.60%
2021 -12.73%
2020 -45.36%
2019 103.37%
2018 -76.28%

Continue Researching ZYNE

Here are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:

Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!